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Sinry The role of chemotherapy m the palliation of patients with advanced st (IIB and
non-small-cel hmg cancer (NSCLC) remains controversiaL We have carried out a chemotherapy study
mphaiing symptom r f, a topc not normally diussed previous similar studim A total of 120 patiets
with lroy advanced or non-smaB-cell hmg cancer (NSCLC) were traed with a moderate-dose
palliative chemotherapy remeconsisting of mitomycin C 8mgm2 i.v. on day 1 (aherate courses),
vinbLiasn 6 mgm-2 i.v. on day 1 and cisplatin 50 mg m-2 i.v. on day I (MVP), repeating every 21 days for a
maximum of six courses. Thirty-eight of 118 assessable patients (32%) achieved an objective response. Patients
with kally advanced disease (stage IIIB) had a significantly better response rate (52%) than those with
metastatic disease (25%) (P<0.01). In 76 out of 110 (69%/.) patients, with tumour-related symptoms including
24 out of 31 patients (78%) with locally advanced diseas, symptoms compeletely disappeared or substantially
improved. In only 15 patients (14%) did symptoms progress during treatment. Symptomatic improvement was
achieved after one course ofchemotherapy in 61% and after two courses in 96% of responding patients. The
schedule was well tolerated- Only 19% developed WHO grade 3/4 nausea/vomiting, and only 3% developed
significant alopecia. Other toxicities were minimal. MVP is a pragmatic inexpensive chemotherapy regimen
that offers useful sympton palliation in patients with advanced NSCLC and merits a 1-2 course therapeutic
trial in such patients. The schedule should also be assessed as prmary (neoadjuvant) chemotherapy before
radical radiotherapy for locally advanced NSCLC in a randomised trial.
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The role of chemotherapy in the treatment of advanced
non-small-cell lung cancer (NSCLC) remains controversial.
Some, but not all, recent trials have shown a survival advan-
tage for combination chemotherapy over best supportive care
in this condition (Cormier et al., 1982; Rapp et al., 1988;
Cartei et al., 1993), and one has shown chemotherapy to be
more cost-effective than supportive care (Jaakkimairn et al.,
1990). Very recently, an overview analysis of seven trials has
confirmed a statistically significant survival benefit, but a
modest one (Souquet et al., 1993), and chemotherapy re-
mains very much a palliative approach.
No single chemotherapy regimen has been shown superior
to others in the treatment ofNSCLC, but best response rates
have consistently been achieved with cisplatin-based regimens
(Veronesi et al., 1988; Luedke et al., 1990). The combination
of isplatin with mitomycin C and vinblasti has been
shown in randomised trials to be one of the most effective
regimens (Ruckdeschel et al., 1986), and this has the advan-
tage over most other combinations of very rarely causing
signiicant alopecia (an important consideration for palliative
treatment). There is a tendency to use cisplatin in high
dosage (100-120mgm-) in many of these regimens, but
this is associated with significnt toxicity, including emesis,
peripheral neuropathy, nephrotoxicity and high-frequency
hearing loss. These problems disappear or are at least very
markedly reduced with moderate-dose cisplatin (50mgm-2)
and probably without significant reduction in efficacy (Hardy
et al., 1989).
We have therefore developed a moderate-dose cisplatin (P)
regimen in combination with mitomycin C (M) and vinblas-
tine (V) (MVP) which is well tolerated with few side-effects
(Hardy et al., 1989). We have previously shown that this
schedule achieves good symptom relief and therefore useful
palliation in a small series of patients. Symptom relief has
not been adequately addressed in most other studies of
chemotherapy for NSCLC. Here we update our results in a
much larger series of patients with emphasis on symptom
relief as well as response rate and toxicity.
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Materak ad m ds
Patient characteristics
A total of 120 patients were entered into this study between
March 1988 and December 1992. Inclusion criteria included:
(i) histologically proven NSCLC; (ii) inoperability; (iii)
tumour-related symptoms; (iv) adequate renal function
(EDTA clearance > 60 ml min-'). There were 82 men and 38
women, with a median age of 56 years (range 29-77).
Disease was staged according to the criteria of Mountain
(1986): 33 patients were stage IIIB and 87 patients stage IV.
Histological review was carried out in all patients, with 60
confirmed as adenocarcinoma, 15 large-cell carcinoma, 34
squamous cell carcinoma and 11 undifferentiated non-small-
ceUl carcinoma. WHO performance status was as follows: 12
patients, PS 0, 75 patients, PS 1; 25 patients, PS 2; eight
patients, PS 3.
Fifty-two patients had received prior treatment. Five had
recurrent disease following surgery. Thirty-two had received
previous radiotherapy (ten radical and 22 palliative). One
patient had received prior conventional combination chemo-
therapy for coexistent hairy cell leukaemia. Fifteen patients
had been previously treated with expermental single-agent
therapy. Experimental agents included: CL 286,558 (Zeni-
platin), eight patients; lonidamine, four patients; mito-
zolomide, one patient; ifosfamide, one patient; carboplatin,
one patient; CB 10-277 (analogue of dacarbazine), one
patient. Patient characteristics are summarised in Table I.
Treatment regimen
All patients received the following regimen: mitomycin C
8 mg m 2 i.v. on day 1 (given on alternate courses), vinblas-
tine 6mgmr-2 (maximum 1Omg) i.v. on day I and cisplatin
50mgm-2 i.v. on day 1, repeated every 21 days. Standard
intravenous pre- and post-treatment hydration was given
with cisplatin. This consisted of 1.51 of normal saline +
40mmol of potassium chloride + 40 mg frusemide over 2 h
pre-cisplatin, followed by 2 1 of normal saline + 40mmol of
potassium chloride over 12 h post-cisplatin. Patients received
prophylactic antiemetic therapy with high-dose metoclopra-
mide and dexamethasone or a 5-HT3 antagonist and dexa-s_.rdg a orinW
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Table I Patient characteristic
Number of patients
Sex
Mak
Female
Age
Median
Range
Stage
Loally advanced (IHB)
Metastatic (IV)
WHO PS
0
2
3
4
Median PS
Histology
Adenocarcinoma
Large cell carcinoma
Squamous cell arcinoma
Undifferentiated carcinoma
Previous treatments
Chemotherapy (exprimetal)
Chemotherapy (conventional)
Surgery
Radiotherapy
Radical
Palliative
120
82
38
56 years
29-77
33
87
12
75
25
8
0
60
15
34
11
15
5
32
10
22
methasone, often as part of separate antiemetic trials. Renal
flmction was checked with 5"Cr-EDTA clearance before alter-
nate courses and the dose of cisplatin reduced as follows:
EDTA >60mlmin-', full dose; 40-60 ml min', 25% dose
reduction; <40 ml min- , no treatment with cisplatin. Treat-
ment was continued until the development of progressive
disease, unacceptable toxicity or to a minimum of six cycles
in patients achieving objective response and/or symptomatic
relief.
Pretreatment investigations and assessment ofresponse and
toxicity
All patients underwent pretreatment physical examination,
including penpheral full blood count (FBC), plasma elect-
rolytes, urea and creatinine, serum liver function tests, 5"Cr-
EDTA clarance and chest radiography. Other more elabor-
ate radiological investigations were only carried out if
chnically indcated. FBC was repeated in patients at the time
of their predicted nadir following the first cycle of treatment.
Following this patients were ased before each treatment
for symptomatic response (see below) and for objective res-
ponse and toxicity according to standard WHO criteria
(Miler et al., 1981).
Complete response (CR) was defined as the disappearance
of all known disease for at least 4 weeks. Partial response
(PR) was defined as > 50% decrease in the sum of the
products of the tumours' longest dimension and its widest
perpendiclar measurement for at least 4 weeks, without the
appearance of new lesions or progression of any one lesion.
Stable disea (SD/NC) was defined as <50% derease or
<25% increase in the size of the measurable disease, without
the appearance of new lesions or progression of any lesion
>25%. Progressive disease (PD) was defined >25% in-
crease in one or more of the measurable lesions or the
appearance of a new lesion(s). Response duration and sur-
vival were calulated from the date of first treatment using
the standard life-table method of Kaplan and Meier (1958).
Assessment ofsymptomatic response
Tumour-related symptoms were recorded at the start of treat-
ment under the following general headings: malaise, pain,
cough, dyspnoea or 'other', which was then specified. Symp-
toms were then reassessed following each course of treatment
with patients asked to grade change in symptoms using
simple descriptive criteria as follows: (i) complete disap-
pearance of symptoms (CR); (ii) good improvement of symp-
toms (PR); (iii) minor or no change of symptoms (NC); (iv)
worse (PD).
Result
Of the 120 patients entered into this study, two patients were
not evaluable for objective and symptomatic response, one
being lost to follow-up before completion of the first treat-
ment cycle, and the other dying of sepsis during the first
cycle. Nine other patients with progressive disease before
completion of the first treatment cycle have been assssed as
PD for both objective and symptomatic response. Seven
patients were excluded from toxicity analysis (six because of
early progression; plus the patient lost to follow-up). Eight
patients were asymptomatic at presentation and were there-
fore not assessable for symptomatic response. All patients
were included in the survival analysis. The median number of
treatment courses given was 3 (range 1-8). Twenty-five
patients completed six courses of treatment.
Objective response andsurvival
Thirty-eight of the 118 patients (32%, 95% CI 24-41%)
achieved an objective response, with one CR and 37 PRs.
Seventeen of 33 patients (52%, 95% CI 31-66%) with
locally advanced disease (stage IIIB) responded compared
with 21 of 85 patients (25%, 95% CI 15-33%) with metasta-
tic disease (stage IV) (P<0.01). During the first two cycles of
chemotherapy, 4 out of the 33 patients with locally advanced
(IIIB) disease had progressive disease (12%). Details of res-
ponse by stage are shown in Table II. Median response
duration for responding patients was 6 months. Median sur-
vival for all patients was 5 months (6 months for locally
advanced patients and 4 months for metastatic disease
patients). Overall survival is given in Figure 1. Median sur-
vival for responding patients was 9 months compared with 4
months for non-responders (P<0.005).
Response related toprevious chemotherapy
Previous treatment with experimental chemotherapy did not
influence response in this study. The response rate for 103
patients who had received no previous chemotherapy was
32% compared with 29% for the 15 patients who had
received previous experimental chemotherapy.
Symptomatic response
Seventy-six of 110 evaluable symptomatic patients had com-
plete disappearance or good improvement in at least one
tumour-related symptom (69%, 95% CI 59-77). Twenty-
four of31 patients (78%) with locally advanced disease had a
symptomatic response compared with 52 of 79 patients
(66%) with metastatic disease. Response for specific symp-
toms was as follows: malaise, 35/66 patients (53%); pain,
44/73 patients (60%); cough, 53/80 patients (66%); dyspnoea,
45/76 patients (59%). Only 15 patients (14%) had progres-
Table I Objective response
Overall
Stage Patents CR response NC PD
IIIB 33 1 16 (52%) 12 4
IV 85 0 21 (25%) 45 19
Total 118 1 37 (32%) 57 23
Two patients notevahuable: one lost tofolow-up beforecompktion of
first treatment cycle; one died ofsepsis during the first cycle.
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Time since start of treatment (years)
F1ge 1 Overall survival. ( ), all patents; (- ), patients
with symptomatic relief; (-.-.-.-.-), patients with no symptomatic
nelief.
Tasbe m Overal symptomatic response
Evahlbkpatients
Total
Stage CR PR NC PD no.
Lcaly advanced 8 16 5 2 31
(IIB)
Metastatic (IV) 9 43 14 13 79
Total (%) 17 (15) 59 (54) 19 (17) 15 (14) 110
sion of symptoms during chemotherapy. Details of sympto-
matic response are given in Table III.
Forty-six of the 76 responding patients (61%) had a symp-
tomatic response after only one course of chemotherapy and
73 (96%) after two courses. Thirty of these had a further
improvement of symptoms with more treatment. Only three
patients who failed to achieve symptomatic relief with two
courses of treatment (4%) gained a symptomatic response
with further treatment.
Thirty-three of 36 patients (92%) with an objective res-
ponse to treatment gained symptomatic relief. However, 43
patients (54%) with no change or progressive disease on
objective response assessment also gained symptomatic
relief.
Those patients who had a symptomatic response to
therapy had a significant survival advantage over those who
did not (median survival 6 months vs 3 months respectively,
P<0.005) (Figure 1). Median symptomatic response dura-
tion was 15 weeks from start of treatment (range 4-65
weeks).
Toxicity
Overall, treatment with this moderate-dose cisplatin regimen
was well tolerated. Haematological toxicty was minimal
(Table IV). Only seven patients (6%) developed WHO grade
3/4 neutropenia, and only four patients (3%) developed
grade 3/4 thrombocytopenia. Two patients developed neutro-
penic fever, but only one of these developed a significnt
neutropenic infection (1%). One other patient died in his
local hospital of presumed neutropenic sepsis. The most
significant adverse effect was emesis, with 22 patients (19%)
developing grade 3/4 nausea and vomiting on at least one
treatment cycle. Alopecia was minimal, with only three
patients (3%) developing signifcant hair loss. Other
signicant side-effects including neuropathy and nephrotox-
icity were rare (Table V).
Dose reductions anddelays
Eleven patients (9%) required a 25% dose reduction during
chemotherapy. In five cases this was due to a reduction in
Table IV Haematological toxicity
WHO grade (% worstfor any course)
0 1-2 3-4
Anaemia 30 61 9
Leucopenia 71 23 6
Thrombocytopenia 92 5 3
Table V Non-haematological toxicity
WHO grade (% worstfor any course)
O 1-2 3-4
Infection 71 26 3
Nausea/vomiting 34 47 19
Alopecia 71 26 3
Mucositis 77 23 0
Diarrhoea 86 14 0
Neuropathy 84 16 0
Nephrotoxicity 94 6 0
Rash 97 3 0
Table VI Cost ofchemotherapy, May 1993
One course (f) Six courses (f)
Mitonycin C 8 mgm2 37.28 111.84 (three courses)
VinbLastine 6mgm-2 11.01 66.06
Cisplatin mgm 2 26.90 161.40
Saline and frusemide 3.24 19.44
Total 78.47 358.74
EDTA clearance below 60 ml min-1, in three patients
because of grade 3/4 leucopenia and in three because of
grade 3/4 thrombocytopenia. No patient stopped treatment
as a result of treatment-induced toxicity.
Chemotherapy costs
The cost of treatment at May 1993 prices for an average
patient of surface area. 1.75 m2 is shown in Table VI.
Chemotherapy does not yet have an established role in the
treatment of non-small-cell lung cancer (NSCLC). In some
respects, this is surpnsing. At least three randomised trials
have shown a statistically significnt survival benefit over
best supportive care (Cormier et al., 1982; Rapp et al., 1988;
Cartei et al., 1993). In one of these trials, the total costs of
supportive care alone exceeded those of chemotherapy be-
cause more in-patient time was required for symptom control
(Jaakkimainen et al., 1990). On the other hand, not all trials
have shown a statistically significnt survival benefit (Ganz et
al., 1989; Woods et al., 1990; Kaasa et al., 1991). Very
recently, an overview analysis of seven such trials has
confirmed an overall reduction in mortality with
chemotherapy (Souquet et al., 1993), but even in the positive
trials the survival benefit has been small at around 4-5
months. In addition, chemotherapy is frequently perceived as
being expensive and toxic. For these reasons, its role as
palliative treatment for NSCLC has remained controversial.
Our results from this study belie some of these critiisms.
First and most important, this MVP schedule achieves useful
symptomatic benefit in around two-thirds of patients. An
interim analysis of another large trial has also suggested
improvement in tumour-related symptoms following chemo-
therapy (Cullen, 1993). This in its own right is a major issue
in palliative therapy, irrespective of survival benefit. Second,
this benefit is achieved with a low incidence of serious side-
effects, particularly in comparison with some other com-
monly used schedules for NSCLC. For example, by careful
choice of drugs we have dramatically reduced the risk of
4 fu% l
2S*mpeomireiduwiNW inMMC
PA Elis etal
369
severe alopecia (3%); for most other schedules this problem
is almost universal. In addition, by using cisplatin in
moderate dosage, we have abolished the risk of severe drug-
induced nephro- and neurotoxicity reported in other studies
(Ruckdeschel et al., 1986; Rapp et al., 1988). Third, this is a
simple and inexpensive regimen; the drug cost of around £78
per course is up to 10-fold cheaper than some other com-
monly used chemotherapy schedules in cancer medicine.
Most of our patients were treated on an overnight in-patient
basis, but the schedule can readily be adapted for day care
use.
Have these benefits been gained at the expense of decreas-
ed efficacy compared with other more intensive and expensive
regimens? Higher dose cisplatin regimens have been advo-
cated for NSCLC (Donnadieu et al., 1991) and at least one
early trial showed a survival benefit in responding patients
for high vs moderate-dose cisplatin (Gralla et al., 1981).
Subsequent trials, however, have in general failed to confirm
this benefit (Klastersky et al., 1986; Ruckdeschel et al., 1986;
Shinkai et al., 1986), and we believe that current evidence
does not justify a high dose of cisplatin when balanced
against significantly increased toxicity. Our own overall
objective response rate and survival results are within the
range reported in most other studies. An exception however
is the so-called MIC (mitomyci-C, ifosfamide and cisplatin)
schedule, one of the most active regimens so far reported
with a response rate of 56% (Cullen et al., 1988). It is
unlikely that selection bias can entirely explain this
difference, and a comparative trial would be useful in assess-
ing the extent to which putative increased efficacy might
outweigh the disadvantages of increased cost and toxicity of
MIC in a palliative setting.
Meanwhile, we believe that MVP, a pragmatic and inex-
pensive chemotherapy regimen, should now be considered as
an established therapy for symptom palliation in patients
with metastatic NSCLC. An important practical point for
clinical management is that symptom relief was usually
achieved after one course ofchemotherapy and nearly always
after two. Palliative MVP chemotherapy should therefore be
given as a therapeutic trial of two courses, and in general
stopped after this if useful symptomatic relief has not been
obtained. This prevents cumulative toxicity in patients failing
to respond and targets more prolonged treatment at patients
receiving real benefit. Furthermore, since objective response
is nearly always associated with symptomatic relief, the latter
can be used in the great majority of patients as evidence of
clinical benefit without the need for elaborate and expensive
restaging investigations including CT scans to confirm objec-
tive response.
Where does chemotherapy go next in NSCLC? An impor-
tant area for study is primary (neoadjuvant) chemotherapy
before surgery or radiotherapy for locally advanced (usually
IIIB) disease. Several trials have already been reported, some
showing significant survival benefit over radiotherapy alone
(Dillman et al., 1990), some showing benefit just below signi-
ficance (LeChevalier et al., 1991) and some showing no
benefit (Morton et al., 1991). Further trials are under way,
including an important one using the MIC schedule (Cullen
et al., 1988), but results are not yet available. If survival
improvement is established for primary chemotherapy in this
context it is likely to be modest. Real clinical benefit will
therefore also depend on cost-effectiveness and low treat-
ment-associated morbidity. In this context, we believe that
this pragmatic low-risk MVP schedule, with established
efficacy and low toxicity, should now be assessed as primary
(neoadjuvant) chemotherapy before radical radiotherapy for
locally advanced NSCLC in a randomised trial.
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